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Introduction
N-terminal  signal  sequences  are  essential  for  the  transloca-
tion of nearly all secretory proteins across the mammalian ER 
(Rapoport, 2007). After cotranslational recognition by the sig-
nal recognition particle, signal-bearing proteins are targeted 
to ER translocons composed of the Sec61 protein-conducting 
channel. The signal sequence then gates open the Sec61 chan-
nel to initiate translocation of the nascent polypeptide across 
the ER membrane. The sequence requirements for a signal to 
carry out these critical steps in translocation are remarkably 
flexible, needing only a hydrophobic core of 7–9 residues 
(von Heijne, 1985). For this reason, it was long thought that se-
quence diversity among natural signals represents degeneracy 
in functional requirements.
In recent years, however, there is growing appreciation 
that substrate-specific differences among signal sequences may 
have  functional  consequences  (Martoglio  and  Dobberstein, 
1998; Hegde and Bernstein, 2006). For example, analyses in 
biochemical and cell culture systems suggests that signals may 
differ in their gating of the Sec61 translocon (Rutkowski et al., 
2001; Kim et al., 2002), dependence on accessory translocation 
factors (Voigt et al., 1996; Fons et al., 2003), overall efficiency 
in mediating translocation (Belin et al., 1996; Levine et al., 
2005; Shaffer et al., 2005), or sensitivity to translocation inhibi-
tors (Besemer et al., 2005; Garrison et al., 2005). Even native 
proteins have been observed to generate small nontranslocated 
populations in the cytosol in a signal sequence–dependent man-
ner (Rane et al., 2004; Shaffer et al., 2005; Kang et al., 2006). 
Thus, signals from different proteins may not be as functionally 
uniform as generally assumed. However, the in vivo relevance 
of these slight and variable differences in efficiency among sig-
nal sequences is poorly studied.
A key issue is whether a native signal-containing protein, 
synthesized in its appropriate cell types in vivo, ever displays 
any appreciable inefficiency in order to generate a biologically 
relevant nontranslocated population. This question is difficult to 
address for several reasons. First, the nontranslocated species 
P
rotein translocation into the endoplasmic reticu-
lum  is  mediated  by  signal  sequences  that  vary 
widely in primary structure. In vitro studies sug-
gest  that  such  signal  sequence  variations  may  corre-
spond to subtly different functional properties. Whether 
comparable functional differences exist in vivo and are 
of sufficient magnitude to impact organism physiology 
is unknown. Here, we investigate this issue by analyzing 
in transgenic mice the impact of signal sequence effi-
ciency for mammalian prion protein (PrP). We find that 
replacement of the average efficiency signal sequence 
of  PrP  with  more  efficient  signals  rescues  mice  from 
neurodegeneration caused by otherwise pathogenic PrP 
mutants  in  a  downstream  hydrophobic  domain  (HD). 
This effect is explained by the demonstration that effi-
cient signal sequence function precludes generation of a 
cytosolically exposed, disease-causing transmembrane 
form of PrP mediated by the HD mutants. Thus, signal 
sequences are functionally nonequivalent in vivo, with 
intrinsic inefficiency of the native PrP signal being re-
quired for pathogenesis of a subset of disease-causing 
PrP mutations.
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would presumably be of very low abundance, representing a few 
percent of total synthesized protein. Second, nontranslocated 
species are likely to be very transient because of their rapid deg-
radation by quality control pathways. Third, in vivo systems are 
largely inaccessible to the same analytical tools typically used 
in vitro and in cell culture. Thus, direct and reliable detection 
of nontranslocated species or direct assays to measure signal 
sequence efficiencies in vivo are exceedingly difficult.
These problems of detection can be circumvented if any 
nontranslocated polypeptides can either be trapped or have mea-
surable and sensitive downstream consequences. Fortuitously, 
certain disease-causing prion protein (PrP) mutants meet these 
requirements and afford a unique opportunity to test whether 
in vivo signal sequences display either appreciable inefficiency 
or functional differences. Mammalian PrP, which is causative 
of various neurodegenerative diseases (Prusiner et al., 1998), 
contains a typical ER signal sequence of apparently average ef-
ficiency (Kim et al., 2002). The normal and primary outcome of 
PrP biosynthesis at the ER is its complete translocation into the 
lumen, where the N-terminal signal sequence is removed, two 
consensus sites become glycosylated, and a C-terminal peptide 
is processed to a glycosylphosphatidylinositol anchor (Fig. 1,   
A and B). However, PrP polypeptides whose signals fail to ini-
tiate translocation have two possible outcomes depending on 
downstream  sequence  elements  (Kim  et  al.,  2001;  Kim  and 
Hegde, 2002; Stewart and Harris, 2003). The first outcome is 
the release of PrP into the cytosol, where it is rapidly degraded 
by a proteasome-dependent pathway. Hence, proteasome in-
hibition permits nontranslocated PrP to accumulate (Ma and 
Lindquist, 2001; Yedidia et al., 2001; Drisaldi et al., 2003), an 
event that can be prevented by a more efficient signal sequence 
(Rane et al., 2004). The second outcome is production of a 
transmembrane isoform of PrP termed 
CtmPrP. This occurs when 
a  highly  conserved  downstream  hydrophobic  domain  (HD)   
engages the translocon before PrP is released to the cytosol 
(Kim and Hegde, 2002). In vitro, both of these outcomes are 
detectable and can be modulated in a predictable fashion by 
changing the properties of the signal sequence and HD (Kim 
et al., 2001, 2002; Kim and Hegde, 2002; Stewart and Harris, 
2003). Thus, both 
CtmPrP and cytosolic PrP (cyPrP) appear to be 
products of signal sequence inefficiency.
Although cyPrP is very difficult to detect in vivo because 
of its rapid proteasomal degradation, 
CtmPrP seems to be signifi-
cantly more stable (Stewart and Harris, 2005). This means that 
CtmPrP represents a “trapped” product of failed translocation. 
Thus, when hydrophobicity of the HD is increased, signal se-
quence inefficiency results in generation of 
CtmPrP (Kim et al., 
2001). Because 
CtmPrP levels are correlated with neurodegener-
ation in mice (Hegde et al., 1998a, 1999; Stewart et al., 2005), 
we reasoned that it should be possible to measure differences in 
signal efficiency in the context of a whole organism. Our strat-
egy was to determine if 
CtmPrP (and the ensuing neurodegenera-
tion) caused by an HD mutant could be rescued by changing the 
signal sequence to one that, based on in vitro studies, should be 
more efficient. This experiment was designed to address four 
inter-related questions of relevance to protein translocation 
and PrP biology. First, are native signal sequences sufficiently 
Figure 1.  Improving signal efficiency reduces 
CtmPrP in vitro. (A) Line dia-
gram of PrP showing elements involved in its translocation. Amino acid resi-
dues of key domains, and the epitopes for the 3F4 and 13A5 monoclonal 
antibodies, are indicated. (B) Steps in PrP translocation. Starting at the left, 
PrP is targeted to a Sec61 translocon via its N-terminal signal sequence. 
The signal then interacts with Sec61 and gates open the channel to initiate 
translocation. Further protein synthesis results in complete translocation into 
the ER lumen to generate 
secPrP. This is the normal pathway followed by the 
majority of PrP polypeptides synthesized. However, intrinsic inefficiencies 
in the signal sequence interaction with the translocon can cause a small 
proportion of PrP polypeptides to fail at the crucial gating/initiation steps. 
The bottom shows the two potential outcomes when signal-mediated gating 
and/or early translocation fails. In the first case, the polypeptide is expelled 
into the cytosol to generate cyPrP. Alternatively, the central HD, particularly 
if it carries a mutation that increases hydrophobicity, can engage the nearby 
translocon to generate 
CtmPrP. (C) Analysis of translocation and topology 
of various PrP constructs in vitro. The indicated constructs were translated 
in reticulocyte lysate containing rough microsomes. The samples were then 
digested with PK and analyzed by SDS-PAGE and autoradiography. The 
diagram illustrates the assay whereby 
secPrP is fully protected from PK diges-
tion, whereas 
CtmPrP is partially digested to generate an 18-kD fragment. The 
ratio of the 
secPrP to 
CtmPrP products for each construct is shown below the in-
dividual lanes. Note that each of the mutations increases 
CtmPrP (i.e., reduced 
sec/Ctm ratio) but is largely reverted when the signal sequence from Prl is 
used. Numbers to the right indicate molecular mass in kD.517 Functional diversity of signal sequences • Rane et al.
Furthermore, 
CtmPrP levels can be substantially normalized back 
toward wild-type levels by the Prl signal sequence. It is worth 
noting that the absolute sec/Ctm ratio values vary somewhat be-
tween different batches of translation extracts and microsomes 
(for example, compare Fig. 1 C to Fig. S1 A). This is presum-
ably because there are trans-acting factors in both the cytosol 
(Lopez et al., 1990) and membrane (Hegde et al., 1998b; Fons 
et al., 2003), whose activities can vary and influence transloca-
tion and topology of PrP. Nonetheless, the key observations that 
HD mutants increase 
CtmPrP relative to wild type, and that the 
Prl signal sequence largely normalizes 
CtmPrP of HD mutants 
back toward normal, are consistently observed.
Analysis of wild-type PrP in cultured cells indicates that 
the  amount  of  nontranslocated  cyPrP  is  10%  of  total  PrP 
synthesized (Rane et al., 2004), with unknown (but assumed 
to be low) levels of 
CtmPrP. This level of signal inefficiency is 
also consistent with estimates derived from artificial reporter 
assays of signal function in mammalian cultured cells (Levine 
et al., 2005). This suggests that the PrP signal is indeed par-
tially inefficient in cells, as seen in vitro. To determine whether 
this inefficiency plays a role in 
CtmPrP production, we turned 
to a previously characterized limited protease digestion assay 
that can discriminate 
CtmPrP from other forms by virtue of its 
slightly different conformation (Hegde et al., 1998a, 1999).
Under the digestion conditions used, properly folded non-
transmembrane PrP forms are trimmed at the unstructured N ter-
minus (up to residue 125), leaving behind an intact C-terminal 
globular domain (GD) that presumably corresponds to the core 
structure seen in nuclear magnetic resonance studies (Riek et al., 
1996, 1997; Donne et al., 1997). In contrast, 
CtmPrP is digested to 
only residue 105, apparently because the membrane-inserted 
HD acquires a different conformation that is retained even after 
detergent solubilization. Thus, the resulting fragment from 
CtmPrP 
(18 kD) is slightly larger than the core GD (15 kD). The 3F4   
monoclonal  antibody,  whose  epitope  falls  within  residues 
109–112, selectively recognizes the 
CtmPrP fragment and is 
therefore invaluable for this assay. The amount of the 
CtmPrP frag-
ment detected by 3F4 can be quantified by comparing to serial 
dilutions of undigested total lysate. Notably, some HD mutants 
within or near the 3F4 epitope (such as KH-II) interfere with 3F4 
antibody binding and therefore must be detected by other   
C-terminal antibodies that detect both 
CtmPrP and GD fragments. 
As a practical matter, this somewhat limits assay sensitivity be-
cause the two fragments migrate closely, proteolysis is not abso-
lutely precise (resulting in some fragment heterogeneity), and the 
CtmPrP fragment is vastly less abundant than the GD fragment.
Using  this  assay, 
CtmPrP  levels  in  transiently  transfected 
cultured cells expressing wild-type PrP were determined to be 
<1–2% (Fig. 2). This suggests that the wild-type HD does not 
engage the translocon with high efficiency in cells. In contrast, 
HD mutants detectably increase 
CtmPrP levels (Fig. 2). The most 
hydrophobic  artificial  HD  mutants  PrP(AV3)  and  PrP(KH-II) 
were roughly equivalent, each producing 10% 
CtmPrP (Fig. 2).   
As expected, PrP(A117V) generated an intermediate level of 4% 
CtmPrP. The increased 
CtmPrP seen with PrP(AV3) was reduced to 
near wild-type levels when the native PrP signal and cleavage site 
were replaced with the corresponding region from Prl (a construct 
different in function in vivo to impact normal physiology? 
Second, is the native PrP signal sequence detectably inefficient 
in vivo? Third, are the in vitro mechanistic models of PrP trans-
location and 
CtmPrP production valid in vivo? Fourth, do HD 
mutations cause disease via 
CtmPrP production, or do they have 
another previously unforeseen effect?
Results
Effect of signal sequence efficiency on 
CtmPrP production in vitro
Several  natural  and  artificial  disease-associated  PrP  mutations 
within  the  HD  were  analyzed  for 
CtmPrP  generation  in  vitro   
using a reticulocyte lysate translation system containing pancre-
atic rough microsomes. The assay for PrP topology in vitro is 
based on protease protection and has been described previously 
(Hegde et al., 1998a; Fig. S1 A). In brief, protease treatment of PrP 
translocation reactions causes 
CtmPrP to be partially digested, fully 
translocated PrP to be completely protected, and nontranslocated 
PrP to be completely digested. The ratio of fully protected PrP 
(operationally termed 
secPrP to indicate its full translocation like 
a secretory protein) to the 
CtmPrP-derived fragment is therefore an 
indicator of how much ER-targeted PrP is generated in the 
CtmPrP 
form. This sec/Ctm ratio was used to assess the PrP mutants.
PrP(A117V),  PrP(G114V),  and  PrP(G131V)  are  each 
natural point mutants in human PrP that increase HD hydro-
phobicity and are associated with the neurodegenerative dis-
ease Gerstmann-Sträussler-Schienker Syndrome (Tateishi et al.,   
1990; Hsiao et al., 1991; Panegyres et al., 2001; Rodriguez et al., 
2005). Of these, rodent PrPs containing the A117V mutation 
have been expressed in transgenic mice and shown to cause neuro-
degeneration (Hegde et al., 1998a; Yang et al., 2009). PrP(AV3) 
is an artificial mutant in rodent PrP that contains three alanine-
to-valine changes within the HD, substantially increases HD 
hydrophobicity, and causes early onset neurodegeneration upon 
expression in transgenic mice (Hegde et al., 1998a). PrP(KH-II) 
is a different type of artificial mutant in rodent PrP that lengthens 
the HD toward the N terminus and presumably shifts slightly the 
residues that would span the bilayer. This too causes neuro-
degeneration in transgenic mice (Hegde et al., 1998a, 1999). As 
expected, each of these HD mutations, when analyzed in vitro, 
generates increased 
CtmPrP relative to wild-type PrP (Fig. 1 C). 
Hence, although wild-type PrP has a sec/Ctm ratio of 5.5, each 
of the HD mutants shows ratios of <1.
Based on earlier studies of PrP translocation (Kim and 
Hegde, 2002), increased 
CtmPrP results from PrP molecules that 
would have failed to be translocated because of an inefficient 
signal sequence, but now insert into the membrane because the 
mutant HD can better engage the translocon (Fig. 1 B). Consis-
tent with this mechanism, the effect of hydrophobic HD mu-
tants was largely reversed in vitro by replacing the somewhat 
inefficient PrP signal sequence with the highly efficient signal 
from the secretory protein prolactin (Prl; Fig. 1 C). This is ap-
parent by the more than fourfold increase in the sec/Ctm ratio 
for each HD mutant that brings it close, but not quite equal, 
to wild-type levels. This suggests that 
CtmPrP generation by 
HD mutants in vitro depends on signal sequence inefficiency. JCB • VOLUME 188 • NUMBER 4 • 2010   518
not influence the behavior or consequences of an HD mutant. 
Thus, changing the native signal sequence of a PrP HD mutant 
to a different signal that in vitro analyses predict is more efficient 
should simultaneously allow two key hypotheses to be tested: 
one concerning the importance of signal sequence efficiency in 
the mechanism of PrP translocation, and another concerning the 
role of 
CtmPrP in mediating the downstream pathogenic conse-
quences of certain inherited disease-associated PrP mutants.
A handful of signal sequences have been characterized and 
compared in vitro, and four HD mutants (AV3, KH-II, A117V, 
and N108I) have been examined in transgenic mice. In choosing 
among these, we decided on the Prl signal sequence and the arti-
ficial PrP(AV3) HD mutant for these studies for several reasons. 
First, the Prl signal sequence is perhaps the best studied mam-
malian signal sequence, and has been found to be highly efficient 
by numerous types of assays. Second, PrP(AV3) is a severely 
pathogenic mutant that leads to early onset disease phenotypes 
(by 50 d of age) that even precluded generation of stable breed-
ing transgenic lines (Hegde et al., 1998a). This means that rescue 
can be assessed without necessarily requiring prolonged obser-
vation times. Third, this mutation does not interfere with 3F4 
antibody recognition (unlike KH-II or, to a lesser extent, N108I), 
which permits a reliable and sensitive assay for 
CtmPrP in brain 
extracts. A notable disadvantage of the AV3 mutation is that 
samples from the original transgenic animals described in Hegde 
et al. (1998a) are not available for direct comparison. However, 
analyses of brain tissue at that time had documented that, as ex-
pected from in vitro and cell culture studies, the proportion of 
PrP in the 
CtmPrP form for PrP(AV3) is very similar to that seen 
for PrP(KH-II), and roughly twofold higher than that seen with 
PrP(A117V) (Fig. S1 B). Importantly, archived samples from 
these key transgenic lines, termed PrP(KH-II)H and PrP(A117V)H, 
were still available for comparison and could therefore serve as 
important standards for biochemical assays for 
CtmPrP levels. 
Thus, on balance, we felt the PrP(AV3) mutation would be the 
best test case for determining whether signal sequence efficiency 
is important to PrP biogenesis and disease in vivo.
A transgene coding for Prl-PrP(AV3) was introduced into 
mice (FVB background) and evaluated for expression, 
CtmPrP 
levels, and the development of neurodegenerative disease. To 
allow direct comparison to earlier studies (Hegde et al., 1998a, 
1999), we used the same transgene vector as previously used 
to analyze PrP(AV3), PrP(KH-II), and PrP(A117V). This vector 
contains 35 kB of the native PrP promoter and has been 
  documented to precisely mirror the expression pattern of na-
tive PrP (Scott et al., 1989; Tremblay et al., 2007). To maximize 
the severity of any phenotype, PrP
+/+ mice were used because 
endogenous PrP was observed in earlier studies to exacerbate   
CtmPrP-mediated neurodegeneration (Stewart et al., 2005).
Three  independent  lines  (designated  with  subscripts  6, 
10,  and  11)  of  Prl-PrP(AV3)  were  generated  and  analyzed. 
In  contrast  to  earlier  PrP(AV3)  mice  (Hegde  et  al.,  1998a),   
Prl-PrP(AV3)  mice  were  propagated  readily  and  showed  no 
gross abnormalities well into adulthood. Expression levels of 
the three mouse lines were analyzed by immunoblotting of total 
brain homogenates and compared with serial dilutions of homog-
enate from the PrP(A117V)H line of transgenic mice (Fig. 3 A).   
termed Prl-PrP[AV3]; Fig. 2). These results mirror the findings 
in vitro in two ways. First, PrP(AV3) and PrP(KH-II) are compa-
rably potent at inducing 
CtmPrP, whereas PrP(A117V) was about 
half as potent. Second, the Prl signal largely normalizes the 
CtmPrP 
increase caused by the AV3 mutation. Thus, in both in vitro and 
cultured cell systems, signal sequence efficiency can modulate the 
amount of 
CtmPrP generation caused by an HD mutation.
Signal sequence efficiency influences 
CtmPrP 
and neurodegeneration in vivo
Because  HD  mutants  expressed  in  transgenic  mice  generate 
biochemically measurable 
CtmPrP and have pathological conse-
quences (Hegde et al., 1998a, 1999), it should be possible to   
analyze signal sequence efficiency in vivo. We therefore rea-
soned  that  highly  efficient  signal  sequences  should  reduce   
CtmPrP levels in the brain of an otherwise 
CtmPrP-producing HD 
mutation. Furthermore, if the proximal cause of neurodegenera-
tion by the HD mutation is via generation of 
CtmPrP (as opposed 
to some other consequence of the mutation), then increasing 
signal sequence efficiency should also alleviate neurodegenera-
tion. However, if 
CtmPrP is generated by a different mechanism 
in vivo, and differences in signal efficiency seen in vitro are in-
consequential in vivo, then changing the signal sequence should 
Figure 2.  Analysis of PrP translocation and 
CtmPrP in cultured cells. Limited 
PK digestion assay for 
CtmPrP in crude microsomes isolated from N2a cells 
transfected with the indicated constructs. Samples were subjected to PK 
digestion under either mild or harsh conditions (as described in Materials 
and methods). The protease-digested samples were deglycosylated with 
peptide-N-glycosidase F and analyzed by immunoblotting alongside serial 
dilutions of untreated samples (first four lanes of each panel). The relative 
amounts loaded in each lane are indicated above the gels. Blots were 
probed with monoclonal antibodies 13A5 (wild-type [WT] and KH-II pan-
els) or 3F4 (other panels). The 
CtmPrP-specific fragment (arrows) and C-terminal 
GD fragment (recognized only by the 13A5 antibody) are indicated. The 
percentage of total PrP in the 
CtmPrP form was quantified and indicated 
below each panel. Numbers on the left indicate molecular mass in kD.519 Functional diversity of signal sequences • Rane et al.
neurodegeneration at mean ages of 58, 472, and 572 d, respec-
tively (Hegde et al., 1999). The comparison to PrP(KH-II)M 
and PrP(KH-II)H mice is particularly noteworthy because the 
AV3 and KH-II mutations have very similar effects on 
CtmPrP 
production in vitro, in cells, and in transgenic mice (Figs. 1, 2, 
and S1; Hegde et al., 1998a), and are comparably pathogenic 
in transgenic mice (Hegde et al., 1998a). Yet, Prl-PrP(AV3)6 
and Prl-PrP(AV3)10 mice were phenotypically normal despite 
expressing the transgene at comparable or even considerably 
higher  levels  than  either  PrP(KH-II)M  or  PrP(KH-II)H  mice 
(Fig. 3 C). In the most striking comparison, Prl-PrP(AV3)6 mice 
express almost eightfold more mutant PrP than PrP(KH-II)M 
mice, yet remain disease free in comparison.
Prl-PrP(AV3)  was  not  entirely  without  consequences, 
as line 11, which expresses the highest level of the transgene 
(5.7×),  developed  signs  of  neurodegenerative  disease  and 
died between 150 and 300 d. This was still considerably lon-
ger than the 60 d course to disease of PrP(KH-II)H, despite 
Previous quantification has shown that PrP(A117V)H, which de-
velops late onset neurodegenerative disease at 570 d of age, 
expresses PrP at 4× the level found in normal hamster brain 
(Hegde et al., 1999). Relative to this standard, lines 6, 10, and 
11 were found to express the transgene at 4.7 ± 0.4, 2.4 ± 0.4, 
and 5.7 ± 0.5, respectively (Fig. 3 B). These expression lev-
els were as high or higher than PrP levels in several transgenic 
lines that developed 
CtmPrP-mediated disease in earlier studies 
(Fig. 3 C). Of note, earlier PrP(AV3) mice, all of which had 
succumbed to early onset disease without producing transgenic 
progeny, expressed the protein at between 1× and 4× (Hegde 
et al., 1998a). Thus, we were able to produce high-expressing 
transgenic lines from Prl-PrP(AV3).
Prl-PrP(AV3)6 and Prl-PrP(AV3)10 had normal lifespans 
of up to 800 d (Fig. 3 D and Table I) and did not show gross 
clinical phenotypes indicative of neurodegeneration. This con-
trasts with earlier PrP(KH-II)H, PrP(KH-II)M, and PrP(A117V)H 
lines of transgenic mice, all of which consistently developed 
Figure 3.  Rescue from a disease-causing HD mutant by improving signal efficiency. (A) Brain homogenates from three individual mice from each of 
the three Prl-PrP(AV3) transgenic lines were compared with serial dilutions of homogenate from PrP(A117V)H mice, which served as a standard. After 
SDS-PAGE, the upper portion of the gel was stained with colloidal coomassie blue, whereas the lower portion was immunoblotted using 3F4 antibody.   
(B) Quantification of two experiments, as in A, showing the PrP(A117V)H standards (black circles) and each transgenic line (mean ± SD; n = 6). Using an 
expression level of 4× for PrP(A117V)H, the expression for lines 6, 10, and 11 were determined to be 2.4×, 4.7×, and 5.7×, respectively. (C) Expression 
levels of Prl-PrP(AV3) lines were compared with previously characterized mouse lines known to produce 
CtmPrP and develop neurodegeneration (Hegde et 
al., 1998a, 1999). The A3922 transgenic line, which expresses at 4×, served as a standard. Two amounts of each sample were loaded, and the blots 
were first stained for total protein with Ponceau S before immunoblotting with 13A5 antibody. The samples were run on two gels, with one set of samples 
(from PrP[KH-II]H) duplicated on each gel to ensure that they were directly comparable. Below the lanes are the quantified expression levels and mean age 
of neurodegeneration taken from either this or earlier studies. “n/a” indicates that disease is not observed in these lines. The vertical black line indicates 
that intervening lanes have been spliced out. (D) Kaplan-Meier survival plots for the indicated transgenic mouse lines. The normal lifespan of this strain of 
mouse in our facility is 600–800 d. The broken line indicates the age at which PrP(AV3) founders were observed to develop signs of disease (Hegde   
et al., 1998a). Numbers to the left of the blots in A and C indicate molecular mass in kD.JCB • VOLUME 188 • NUMBER 4 • 2010   520
Because Prl-PrP(AV3)11 develops disease at earlier ages 
than PrP(A117V)H mice (200 d versus 570 d), we compared 
their respective 
CtmPrP levels more closely (Fig. 4 B). Analysis 
of multiple animals showed 1.3-fold more 
CtmPrP in the Prl-
PrP(AV3)11 mice. Although this difference is rather modest, we 
believe  it  likely  explains  the  more  severe  phenotype  because 
  earlier studies suggested a steep relationship between 
CtmPrP 
and  age  of  disease  onset.  For  example,  the AV3  and  KH-II 
  mutations increase 
CtmPrP levels by only approximately twofold 
relative to A117V in vitro (Fig. 1 and Fig. S1; Hegde et al., 
1998a), in cells (Fig. 2), and in transgenic mice (Fig. S1), yet are 
substantially more pathogenic and cause disease at both earlier 
ages and lower expression levels (Hegde et al., 1998a, 1999).
The quantification of 
CtmPrP in Prl-PrP(AV3)11 relative to 
PrP(A117V)H, combined with knowledge of the total PrP ex-
pression level in these mice, also allowed us to estimate the 
proportion of 
CtmPrP generated by Prl-PrP(AV3). As shown in the 
supplementary data of Chakrabarti and Hegde (2009), 6% of 
the PrP in PrP(A117)H mice is in the 
CtmPrP form. Given that Prl-
PrP(AV3)11 contains 1.3-fold more 
CtmPrP but 1.5-fold more 
total PrP, we conclude that a lower proportion of Prl-PrP(AV3) 
molecules are made as 
CtmPrP relative to the proportion generated 
by PrP(A117V) (5% compared with 6%). This conclusion is 
further supported by the observation that Prl-PrP(AV3)6 has less 
overall 
CtmPrP  than  PrP(A117V)H  despite  expressing  slightly 
higher total PrP (Fig. 4 A). Thus, the Prl signal substantially re-
duces the generation of 
CtmPrP by the AV3 mutation in transgenic 
mice to less than that seen for the A117V mutation. This reduc-
tion of 
CtmPrP corresponds to substantial attenuation of the neuro-
degenerative phenotype normally caused by the AV3 mutation.
Rescue of a natural human disease mutant 
by improving signal sequence efficiency
The AV3 mutation is an artificial and exaggerated version of 
naturally occurring HD mutations that cause human disease. 
The  studies  on  Prl-PrP(AV3)  therefore  represented  a  useful 
the fact that Prl-PrP(AV3)11 expresses the transgene at nearly 
twofold higher levels and in the PrP
+/+ background. When taken 
together, our data suggest that replacing the wild-type PrP sig-
nal sequence with that from Prl renders the AV3 mutation con-
siderably less pathogenic than it would be otherwise, permitting 
high-level expression (up to 4.7×) without obvious adverse 
consequences or a gross diminishment of lifespan.
To determine whether the phenotypic rescue effected by 
changing the signal sequence was caused by more efficient PrP 
translocation, brain tissue from Prl-PrP(AV3) mice was analyzed 
for 
CtmPrP using the limited protease digestion assay (Fig. 4 A).   
We found that all of the Prl-PrP(AV3) samples had lower total 
levels of 
CtmPrP than that seen with the PrP(KH-II)H–positive 
control, which earlier studies have shown to generate similar 
levels of 
CtmPrP as PrP(AV3) (Fig. S1; Hegde et al., 1998a). 
It is worth emphasizing that equal amounts of brain homog-
enate were analyzed, meaning that total PrP levels in the Prl-
PrP(AV3)6 and Prl-PrP(AV3)11 samples were 1.6- and 1.9-fold 
higher  than  in  the  PrP(KH-II)H  sample. Thus,  Prl-PrP(AV3) 
brain tissue not only contains less overall 
CtmPrP, but must nec-
essarily be generating a considerably lower proportion of total 
PrP in the 
CtmPrP form relative to PrP(KH-II). This observation 
argues strongly that replacing the native PrP signal sequence on 
PrP(AV3) with that from Prl dramatically reduces 
CtmPrP pro-
duction similar to in vitro and cultured cell analyses.
Overexposure of the blot revealed that 
CtmPrP in the higher-
expressing Prl-PrP(AV3) lines was indeed detectable, and com-
parable to (line 11) or lower than (lines 6 and 10) that seen for 
PrP(A117V)H and PrP(KH-II)M (Fig. 4 A). Thus, there was a 
good general correlation between absolute amounts of 
CtmPrP as 
observed by this assay and development of neurodegeneration: 
PrP(KH-II)H shows very early onset disease and has the most 
CtmPrP; PrP(KH-II)M, PrP(A117V)H, and Prl-PrP(AV3)11 have 
comparatively  late-onset  disease  and  clearly  lower  levels  of   
CtmPrP; Prl-PrP(AV3)6 and Prl-PrP(AV3)10 have the least 
CtmPrP 
and do not develop obvious disease.
Table I.  Characteristics of transgenic mice
Transgene
a Expression level
b CtmPrP in vitro
c CtmPrP in cells
CtmPrP in vivo
d Time to disease
% % d
PrP(A3922) 4.0× 10 <2 <2 >700
PrP(KH-II)H 3.0× 30 10 10–20 60
PrP(KH-II)M 0.6× 30 10 5–8 470
PrP(A117V)H 4.0× 15 4 5–8 570
PrP(AV3) 1–4× 35 10 10–20 <60
Prl-PrP(AV3)6 4.7× 15 <2 2–5 >600
Prl-PrP(AV3)10 2.4× 15 <2 <2 >600
Prl-PrP(AV3)11 5.7× 15 <2 5–8 200
HuPrP(A117V)36 2.4× 15 4 ND
e 560
Opn-(A117V)33 4.0× 10 <2 ND
e >700
aThe first five transgenic lines have been described previously (Hegde et al., 1998a, 1999).
bRelative to PrP levels in normal hamster (defined as 1×).
cPercentage of total PrP from a typical experiment. Exact amounts vary depending on experimental conditions and variations in the translation extract and ER micro-
somes. However, the relative relationships remain constant.
dArbitrary units; determined by comparing the amount of the diagnostic 18-kD band generated by limited PK digestion to a serial dilution of total brain homogenate.
eIndicates not determined; the precise amounts could not be quantified because human PrP seems to behave slightly differently than rodent PrP in the limited PK   
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To test this idea directly, we sought to analyze the human 
A117V mutant, which has successfully been modeled in trans-
genic mice (Hegde et al., 1999). This, however, posed some ex-
perimental limitations (hence the reason for initially focusing 
on the more tractable AV3 mutant). First, because the A117V 
mutation causes a relatively late-onset disease, any rescue 
would necessarily be modest because normal aging phenotypes 
and death will occur at only slightly later times. In fact, a rescue   
effect may be most apparent simply as the ability to express 
higher levels of the transgene without phenotypic consequences. 
Second, cell culture experiments suggest that the limited pro-
teinase K (PK) digestion assay for analyzing 
CtmPrP is not as 
robust for human PrP (HuPrP) as with rodent PrP (unpublished 
data). For reasons that are not entirely clear, the subtle differ-
ence in conformation between 
CtmPrP and other PrP forms is not 
as readily maintained for HuPrP in detergent lysates, making 
model system to analyze whether signal sequence inefficiency 
is involved in 
CtmPrP production in vivo, and to determine if 
CtmPrP has a causative role in neurodegenerative disease. Two 
key observations from in vitro analyses suggest that this model 
system can likely be generalized to natural HD mutations. First, 
each of the HD mutations, regardless of where within the HD 
they are located, are similarly reduced in their 
CtmPrP production 
by the Prl signal sequence (Fig. 1 C). Second, other efficient 
signal sequences can have the same effects as the Prl signal in 
reducing 
CtmPrP of HD mutations (Kim et al., 2002; Kim and 
Hegde, 2002), which suggests that the Prl signal is not unique. 
Thus, although based on experiments in heterologous in vitro 
systems, it seemed plausible to extrapolate our in vivo findings 
with Prl-PrP(AV3) and hypothesize that natural HD mutations 
generate disease-inducing 
CtmPrP because of signal sequence in-
efficiency, and hence can be rescued by an efficient signal.
Figure 4.  Increased signal efficiency reduces 
CtmPrP levels in transgenic mice. (A) Mouse brain homogenates from the indicated transgenic mice were 
subjected to limited PK digestion under “mild” conditions (see Materials and methods) and PrP detected by immunoblotting (two exposures, as well as 
total protein staining of the blot, are shown). The diagnostic 
CtmPrP-specific fragment and C-terminal GD that resists digestion under these conditions are 
indicated. The relative amounts of each sample loaded on the gel are indicated above the lanes. No signal was seen on the blot of samples digested under 
“harsh” conditions (not depicted). (B) Direct comparison of 
CtmPrP levels in three Prl-PrP(AV3) line 11 animals relative to PrP(A117V)H. Quantification showed 
1.3× higher 
CtmPrP in Prl-PrP(AV3)11. A3922 expresses wild-type PrP at 4×, and serves as a negative control. It contains very low, but detectable, levels 
of 
CtmPrP. Numbers to the sides of the blots indicate molecular mass in kD.JCB • VOLUME 188 • NUMBER 4 • 2010   522
it quite difficult to detect 
CtmPrP and even harder to see small 
differences. And finally, A117V generates a rather small pro-
portion of total PrP as 
CtmPrP (only 4–6%), making its further 
reduction more challenging to assess.
These potential obstacles notwithstanding, we generated 
transgenes for HuPrP(A117V) and a version of HuPrP(A117V) 
containing the signal sequence from the hormone osteopontin 
(termed Opn-HuPrP[A117V]). Earlier studies have shown that 
the Opn signal sequence is more efficient than the PrP signal 
(Kim et al., 2002; Levine et al., 2005), that it can improve PrP 
translocation in cell culture (Rane et al., 2004), and that it can 
reduce 
CtmPrP levels of HuPrP(A117V) to near wild-type levels 
in vitro (Kim and Hegde, 2002). Introduction of these transgenes 
into the FVB strain of PrP
+/+ mice generated several founders, 
the progeny of which were analyzed for expression levels (Fig. 5, 
A and B). Lines 34 and 36 of HuPrP(A117V) expressed the 
transgene at 8× and 2.4×, respectively. Of these, line 34 could 
not be analyzed further because the F1 progeny showed erratic 
behavioral abnormalities such as hyperactivity and locomotor 
problems that prevented their further breeding and expansion. 
We therefore focused on HuPrP(A117V)36, which generated a 
colony of mice that were then observed throughout their life-
times. Opn-HuPrP(A117V) also produced two lines whose ex-
pression levels were 4× (line 33) and 8× (line 31), both of which 
produced sufficient animals for observation and analysis. Line 31, 
which  developed  various  phenotypes  and  died  prematurely 
(Fig. 5 C), was not considered in detail because overexpression 
of even wild-type PrP at these levels causes an atypical disease 
that confounds analyses (Westaway et al., 1994; Chiesa et al., 
2008). This  left  HuPrP(A117V)36  and  Opn-HuPrP(A117V)33 
for comparative phenotypic analyses.
Similar  to  previous  studies  overexpressing  rodent 
PrP(A117V) in mice (Hegde et al., 1999; Yang et al., 2009), 
HuPrP(A117V)36  displayed  a  slightly  shortened  mean  life-
span  of  560  d  relative  to  the  usual  600–800  d  lifespan 
expected for our mouse facility (Fig. 5 C). In contrast, Opn-
HuPrP(A117V)33, which was produced at the same time, main-
tained in the same facility, and characterized in parallel, had 
a normal 710 d mean lifespan (Fig. 5 C). Although this dif-
ference in overall lifespan is rather modest, it was statistically 
significant  (P  =  0.02)  using  the  log-rank  test  for  evaluating 
survival data (Peto and Peto, 1972). Furthermore, the effect is 
actually the most it could have been given the mean 2-yr life-
span of normal FVB mice in our facility and elsewhere. Indeed,   
although large numbers of nontransgenic mice were not system-
atically maintained for their entire lifetimes because of space 
and cost constraints, we have not observed any mice living lon-
ger than the Opn-HuPrP(A117V)33 line. In addition to this mod-
est lifespan increase, there are several further observations that 
Figure 5.  Effect of improving signal efficiency on a human disease-
causing HD mutant. (A) Analysis of expression levels for the indicated 
transgenic mice using serial dilutions of the A3922 mouse as a standard. 
The blot was first stained for total protein with Ponceau S, followed by   
immunodetection with 3F4. All samples were analyzed on the same gel and 
are shown from the same exposure. The black vertical line indicates the 
position where an irrelevant lane was spliced out of the image. Numbers 
to the left indicate molecular mass in kD. (B) Quantification of expression 
 
levels in the indicated transgenic lines relative to PrP(A117V)H standards. 
Individual data points are shown. From this experiment, we calculated that 
HuPrP(A117V)36 expresses at 2.4 ± 0.3×, whereas Opn-HuPrP(A117V)33 
expresses at 4 ± 0.2×. (C) Kaplan-Meier survival plots for the indicated 
transgenic mouse lines. The data for HuPrP(A117V)36 was compared with 
Opn-HuPrP(A117V)33 using the log-rank test and found to be statistically 
different (P = 0.02).523 Functional diversity of signal sequences • Rane et al.
Third, although direct detection of 
CtmPrP for human PrP 
has not been possible yet because of technical constraints, there is 
nonetheless reason to believe that the Opn signal sequence has re-
duced the 
CtmPrP levels of the A117V mutation. This comes from 
the analysis of mahogunin, a cytosolic protein that can interact 
with 
CtmPrP via the cytosolically exposed N terminus (Chakrabarti 
and Hegde, 2009). We found that mahogunin immunoreactivity 
is altered in some brain regions of HuPrP(A117V)36 mice, but is 
largely normal in Opn-HuPrP(A117V)33 mice (Chakrabarti and 
Hegde, 2009), which suggests indirectly that cytosolic exposure 
of PrP was reduced by the Opn signal sequence.
Thus,  when  lifespan  differences,  clinical  phenotypes, 
expression  levels,  and  downstream  effects  on  mahogunin 
are considered together, it is reasonable to suggest that Opn-
HuPrP(A117V)33 represents a phenotypically rescued version 
of HuPrP(A117V)36. This conclusion is also most congruent with 
the observation that the Opn signal sequence reduces 
CtmPrP lev-
els of HuPrP(A117V) to near wild type in vitro. Because two 
different HD pathogenic mutants (AV3 and A117V) were res-
cued by two different efficient signal sequences (from Prl and 
Opn), we believe that the phenotypic effects can confidently be 
attributed to a reduction of 
CtmPrP generation by improving 
native PrP signal sequence efficiency.
Discussion
Our results suggest that protein translocation into the ER of 
a native protein in vivo is not necessarily maximally efficient. 
indicated the Opn signal sequence had effected a rescue of the 
HuPrP(A117V) phenotype.
First,  Opn-HuPrP(A117V)33  expresses  the  transgene  at 
higher levels than HuPrP(A117V)36, with the difference corre-
sponding to 1.6 expression units (4× vs. 2.4×). This is not in-
consequential given that an expression level difference of even 
smaller magnitude (5.7× vs. 4.7×) between Prl-PrP(AV3)11 and 
Prl-PrP(AV3)6  is  sufficient  to  have  clear  phenotypic  conse-
quences.  Similarly,  PrP(KH-II)H  and  PrP(KH-II)M  differ  by 
2.4 expression units (3× vs. 0.6×), which corresponded to a 
difference in disease development of 60 d versus 470 d. The 
fact that Opn-HuPrP(A117V)33 discernibly increases lifespan 
despite substantially higher transgene expression compared to 
HuPrP(A117V)36 is therefore notable.
Second, beginning at 18 mo of age, HuPrP(A117V)36 
mice can be distinguished from Opn-HuPrP(A117V)33 mice 
because the former, but the not latter, have a hunched posture, 
altered gait, and/or reduced hind-limb strength (Fig. 6, A–C). 
Many of the HuPrP(A117V)36 mice also showed altered loco-
motor behavior including repeated circling, lethargy, and de-
creased  responsiveness  to  external  stimuli  (Fig.  S2).  Such 
phenotypes were not seen in Opn-HuPrP(A117V)33 mice even 
at ages >2 yr, which indicates a more substantive rescue than 
suggested by overall lifespan alone. Consistent with these dif-
ferences in clinical phenotypes, immunohistochemistry showed 
slightly increased astrogliosis (detected as increased glial fibril-
lary acidic protein [GFAP] staining) in HuPrP(A117V)36 rela-
tive to Opn-HuPrP(A117V)33 (Fig. 6 D).
Figure 6.  Phenotypic rescue in transgenic mice upon improving signal efficiency. (A) The smaller size of HuPrP(A117V)36 mice often seen at older ages 
(which is indicative of some wasting) is not seen for Opn-HuPrP(A117V)33. Some HuPrP(A117V)36 mice also show kyphosis (hunched posture; arrow).   
(B) The rough hair coat in HuPrP(A117V)36 mice, often an indicator of reduced grooming activity, is not seen in Opn-HuPrP(A117V)33. (C) Evidence of hind 
limb weakness in HuPrP(A117V)36 mice, but not in Opn-HuPrP(A117V)33. The top two images in each panel show successive steps during normal walking. 
The bottom images show side views. Note that the HuPrP(A117V)36 mouse is lower to the ground and the tail drags. In contrast, the Opn-HuPrP(A117V)33 
mouse keeps its posterior and tail elevated during walking. (D) Staining of brain sections from 2-yr-old HuPrP(A117V)36 and Opn-HuPrP(A117V)33 mice for 
astrogliosis using anti-GFAP antibody. A region of the hippocampus is shown. Bars, 50 µm.JCB • VOLUME 188 • NUMBER 4 • 2010   524
all of which involve signal sequence inefficiency, that lead to the 
common detrimental endpoint of PrP mislocalization (Chakrabarti 
et al., 2009). Our recent finding that cytosolically mislocalized 
PrP interacts with and disturbs the function of the E3 ubiquitin 
ligase mahogunin provides at least one mechanistic basis for the 
downstream consequences of cyPrP exposure (Chakrabarti and 
Hegde, 2009).
Finally, it is worth considering why, if cytosolic mislocal-
ization is detrimental, PrP has evolved to contain a less than 
maximally efficient signal sequence. One answer to this ques-
tion may have to do with the finding that a suboptimal signal se-
quence is more easily modulated by trans-acting factors (Fons 
et al., 2003; Kang et al., 2006; Hegde and Kang, 2008), thereby 
providing the cell more flexibility. Indeed, the “weak” PrP sig-
nal sequence is beneficial and protective during ER stress be-
cause it facilitates reduced translocation into the ER, thereby 
preventing PrP aggregation in the secretory pathway (Kang 
et al., 2006). Thus, it may be that the potential advantages of a 
suboptimal but regulatable signal sequence outweigh the ex-
ceedingly low risk of adverse post-reproductive consequences 
represented by very rare inherited HD mutants and other PrP-
mediated disorders.
Materials and methods
Antibodies
A 3F4 mouse monoclonal antibody against PrP (Covance) in the form of 
ascites was used at 1:10,000 dilution in Western blots. The 13A5 mono-
clonal antibody against PrP has been described previously (Rogers et al., 
1991) and was used at 1:10,000 for blotting. Anti-GFAP rabbit polyclonal 
antibody was obtained from Novus Biologicals and diluted 1:1,000 for 
immunohistochemistry.
Description of transgenes
The homozygous A3922 line of transgenic mice has been described previ-
ously (Hegde et al., 1998a), and expresses wild-type Syrian hamster PrP 
(SHaPrP) at 4× the level of that found in normal hamster brain. PrP(KH-II) 
describes a mutation in which residues 110 and 111 of SHaPrP are mu-
tated to isoleucines (Hegde et al., 1998a). The “H” and “M” transgenic 
lines of PrP(KH-II) have been characterized previously in the FVB/PrP
/ 
background, and have been shown to develop neurodegeneration at 60 
and 470 d, respectively (Hegde et al., 1998a, 1999). They typically 
died or were sacrificed within a few days after obvious symptoms were 
documented. PrP(A117V)H is a transgenic line expressing an alanine- 
to-valine change at position 117 in SHaPrP (Hegde et al., 1999). Expres-
sion levels are exactly the same as A3922. PrP(AV3) has been described 
previously, and when expressed as a transgene, causes early onset neuro-
degenerative disease (Hegde et al., 1998a). Multiple individual founder 
animals have been characterized, but none were stably established into 
breeding colonies. Disease was seen in animals with expression levels 
ranging from 1× to 4×. The Prl-PrP(AV3) construct was made by replacing 
the signal sequence and cleavage site (residues 1–25 of PrP) with the cor-
responding region (residues 1–33) of bovine preprolactin. Exchanging just 
the signals (residues 1–22 of PrP with residues 1–30 of Prl) caused some-
what heterogeneous signal cleavage in vitro. Thus, to ensure uniformity of sig-
nal cleavage, the signal and cleavage sites were exchanged. HuPrP(A117V) 
is human PrP containing the A117V mutation. Opn-HuPrP(A117V) contains 
the Opn signal sequence (residues 1–16) in place of the PrP signal (resi-
dues 1–22). In this case, signal cleavage heterogeneity was not observed, 
and previous analyses showed cleavage to be occurring at the expected 
position (Rane et al., 2004).
Transgenic mouse production and analysis
The open reading frames coding for the indicated PrP constructs were sub-
cloned into the Cos-tet cosmid containing 35 kb of the native PrP pro-
moter (Hegde et al., 1998a) and expressed as transgenes in FVB mice. To 
maximize the severity of the phenotype (if any) caused by 
CtmPrP, the new 
We estimate that the failed translocation rate of wild-type PrP in 
physiologically appropriate cell types in vivo is roughly 10%, 
which is consistent with earlier in vitro and cell culture mea-
surements (Kim et al., 2002; Rane et al., 2004; Levine et al., 
2005; Kang et al., 2006). This means that the PrP signal se-
quence has substantial room for improvement in efficiency, as 
indicated by the striking consequences of the model Prl signal, 
which appears to be 96–98% efficient. These findings may be 
generally applicable to many other secretory proteins because 
both the sequence features (length, hydrophobicity, amino acid 
composition, and general domain structure) and functional 
properties (efficiency and interaction with translocon factors) of 
the PrP signal are rather typical of many ER targeting signals.
Indeed, several other signal sequences in their native 
context (e.g., from calreticulin [Shaffer et al., 2005], p58
IPK 
[Rutkowski et al., 2007], and corticotropin-releasing factor 
receptor [Kang et al., 2006]) seem to be less than optimally effi-
cient  as  judged  by  the  ability  of  the  Prl  signal  to  improve 
translocation in vitro and/or in cells. Thus, around 5–10% of 
many secretory and membrane proteins might be constitutively 
mislocalized, presumably requiring their rapid degradation by 
the proteasome. Conversely, reduced proteasome activity, a feature 
of many diseases as well as normal aging (Chondrogianni and   
Gonos, 2005), may partially stabilize nontranslocated proteins. 
Similar to PrP (Ma et al., 2002), failed translocation of other 
proteins such as amyloid precursor protein and calreticulin can 
have biological effects in the cytosol (Anandatheerthavarada 
et al., 2003; Shaffer et al., 2005). Thus, the normally minor and 
transient nontranslocated population of several proteins could 
become physiologically or pathologically important under cer-
tain conditions.
For PrP, signal sequence insufficiency appears to play a 
direct role in at least a subset of familial diseases. Generation 
of disease-associated 
CtmPrP by HD mutations depends on the 
slight but measurable inefficiency of the PrP signal sequence. 
Both the disease phenotype and 
CtmPrP can be attenuated by im-
proving signal sequence efficiency, strongly arguing for 
CtmPrP 
produced by these mutations as a primary pathogenic molecule. 
Thus, PrP HD mutants do not appear to be intrinsically toxic 
per se; instead, it is the consequence of the mutation for PrP 
localization that seems to be the key event in causing the dis-
ease phenotype. This explains how a pathogenic mutation (e.g., 
HuPrP[A117V])  can  be  rendered  nonpathogenic  by  making 
second-site changes to a part of the open reading frame that is 
not even part of the final protein.
When combined with earlier observations that increased 
generation of nontranslocated PrP (by weakening or deleting 
the signal sequence) can cause neurodegeneration (Ma et al., 
2002; Rane et al., 2008), it appears that prolonged or increased 
cytosolic exposure of PrP as either cyPrP or 
CtmPrP is especially 
detrimental in vivo. This could arise by any of several mecha-
nisms  including  reduced  PrP  translocation  during  ER  stress 
(Kang et al., 2006; Orsi et al., 2006), decreased proteasomal ac-
tivity during prion infection and/or aging (Chondrogianni and 
Gonos, 2005; Kristiansen et al., 2007), mutations that lead to 
increased 
CtmPrP (Hegde et al., 1998a), or a combination of 
these effects. Thus, there may be multiple different mechanisms, 525 Functional diversity of signal sequences • Rane et al.
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transgenic lines were made in the PrP
+/+ background because this was 
shown previously to accelerate 
CtmPrP-mediated neurodegeneration (Stewart 
et al., 2005). Thus, the fact that Prl-PrP(AV3) in the PrP
+/+ background is 
far less pathogenic than PrP(AV3) in the PrP
/ background is even more 
remarkable. Transgenic animal production, genotyping, and maintenance 
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were observed at least twice weekly, and any abnormal phenotypes were 
noted. In particular, unusual size, locomotor activity, gait, seizure, hair ap-
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served in mouse models of PrP-mediated neurodegeneration, were noted. 
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package “R” (http://www.r-project.org/). In instances where the differ-
ence is visually obvious, exact p-values are not given but were all found 
to be <10
4. The more modest difference between HuPrP(A117V)36 and 
Opn-HuPrP(A117V)33 was statistically significant at P = 0.02. Histological 
analysis for astrogliosis was performed on formalin-fixed paraffin sections 
of brain tissue with anti-GFAP polyclonal antibody and Vectastain ABC de-
velopment reagents (Vector Laboratories), according to the manufacturer’s 
instructions. Sections were subsequently counterstained with hematoxylin 
and mounted with mounting medium (Vectamount; Vector Laboratories). 
Brightfield imaging was performed using an upright microscope (Eclipse 
E600) and a 20×, 0.75 NA, air objective (all from Nikon). Images were 
captured  using  a  digital  camera  (DXM1200F;  Nikon)  with  the  accom-
panying software. The images were imported as 8-bit TIFF images into   
Photoshop (Adobe), where they were subsequently cropped as needed, 
and incorporated into figures prepared using Illustrator (Adobe).
Biochemical analyses
In vitro translocation assays, analyses of 
CtmPrP in cultured cells, and analy-
ses of 
CtmPrP in mouse brain have been described previously (Hegde et al., 
1998a). As detailed before (Hegde et al., 1998a), 
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Online supplemental material
Fig. S1 shows a comparative analysis of mutant PrP translocation in vitro 
and in vivo. Fig. S2 shows that locomotor phenotypes of HuPrP(A117V) 
mice are rescued by the Opn signal. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.200911115/DC1.
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